JP6014592B2 - ペプチド放射性トレーサー組成物 - Google Patents

ペプチド放射性トレーサー組成物 Download PDF

Info

Publication number
JP6014592B2
JP6014592B2 JP2013524419A JP2013524419A JP6014592B2 JP 6014592 B2 JP6014592 B2 JP 6014592B2 JP 2013524419 A JP2013524419 A JP 2013524419A JP 2013524419 A JP2013524419 A JP 2013524419A JP 6014592 B2 JP6014592 B2 JP 6014592B2
Authority
JP
Japan
Prior art keywords
met
gly
cys
peptide
cmbp
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
JP2013524419A
Other languages
English (en)
Japanese (ja)
Other versions
JP2013540702A (ja
JP2013540702A5 (OSRAM
Inventor
アイヴソン,ピーター・ブライアン
バッラ,ラジーブ
インドレヴォール,バード
ゲトヴォルドセン,ギャレス
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GE Healthcare Ltd
Original Assignee
GE Healthcare Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GE Healthcare Ltd filed Critical GE Healthcare Ltd
Publication of JP2013540702A publication Critical patent/JP2013540702A/ja
Publication of JP2013540702A5 publication Critical patent/JP2013540702A5/ja
Application granted granted Critical
Publication of JP6014592B2 publication Critical patent/JP6014592B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K49/00Preparations for testing in vivo
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K51/00Preparations containing radioactive substances for use in therapy or testing in vivo
    • A61K51/02Preparations containing radioactive substances for use in therapy or testing in vivo characterised by the carrier, i.e. characterised by the agent or material covalently linked or complexing the radioactive nucleus
    • A61K51/04Organic compounds
    • A61K51/08Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins
    • A61K51/088Peptides, e.g. proteins, carriers being peptides, polyamino acids, proteins conjugates with carriers being peptides, polyamino acids or proteins
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K7/00Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64Cyclic peptides containing only normal peptide links
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides
    • A61K38/16Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/18Growth factors; Growth regulators
    • A61K38/1833Hepatocyte growth factor; Scatter factor; Tumor cytotoxic factor II

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Optics & Photonics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Physics & Mathematics (AREA)
  • Organic Chemistry (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Nuclear Medicine (AREA)
JP2013524419A 2010-08-18 2011-08-11 ペプチド放射性トレーサー組成物 Active JP6014592B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB1013808.9 2010-08-18
GBGB1013808.9A GB201013808D0 (en) 2010-08-18 2010-08-18 Peptide radiotracer compositions
PCT/EP2011/063890 WO2012022676A1 (en) 2010-08-18 2011-08-11 Peptide radiotracer compositions

Publications (3)

Publication Number Publication Date
JP2013540702A JP2013540702A (ja) 2013-11-07
JP2013540702A5 JP2013540702A5 (OSRAM) 2014-09-18
JP6014592B2 true JP6014592B2 (ja) 2016-10-25

Family

ID=42938098

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2013524419A Active JP6014592B2 (ja) 2010-08-18 2011-08-11 ペプチド放射性トレーサー組成物

Country Status (19)

Country Link
US (1) US9533059B2 (OSRAM)
EP (1) EP2605802B1 (OSRAM)
JP (1) JP6014592B2 (OSRAM)
KR (1) KR101853993B1 (OSRAM)
CN (1) CN103153350B (OSRAM)
AU (1) AU2011290856B2 (OSRAM)
BR (1) BR112013003469A2 (OSRAM)
CA (1) CA2807491C (OSRAM)
CL (1) CL2013000483A1 (OSRAM)
ES (1) ES2626410T3 (OSRAM)
GB (1) GB201013808D0 (OSRAM)
IL (1) IL224463A (OSRAM)
MX (1) MX348733B (OSRAM)
MY (1) MY163136A (OSRAM)
NZ (1) NZ606466A (OSRAM)
PH (1) PH12013500270A1 (OSRAM)
RU (1) RU2594167C2 (OSRAM)
SG (1) SG187878A1 (OSRAM)
WO (1) WO2012022676A1 (OSRAM)

Cited By (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507620A (ja) * 2011-12-20 2015-03-12 ジーイー・ヘルスケア・リミテッド 患者選別方法
US10300156B2 (en) 2013-12-18 2019-05-28 Ge Healthcare Limited Radiotracer compositions and methods
US10548995B2 (en) 2013-08-21 2020-02-04 Ge Healthcare Limited Radiolabelling method

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB201103696D0 (en) * 2011-03-04 2011-04-20 Ge Healthcare Ltd Technetium labelled peptides
GB201209082D0 (en) * 2012-05-24 2012-07-04 Ge Healthcare Ltd Purification method
GB201221266D0 (en) * 2012-11-27 2013-01-09 Ge Healthcare Ltd Aldehyde compositions
GB201322451D0 (en) * 2013-12-18 2014-02-05 Ge Healthcare Ltd Purification method and compositions
US20190151483A1 (en) * 2016-07-25 2019-05-23 The United States Of America, As Represented By The Secretary, Department Of Health And Human Serv Methods of making 18f-labeled precursors and peptides, labeled c-met binding peptides, and methods of use thereof
GB201804835D0 (en) * 2018-03-26 2018-05-09 Ge Healthcare As Formulation and method of preparation
BR112021025124A2 (pt) 2019-06-14 2022-01-25 Edinburgh Molecular Imaging Ltd Composto, composição farmacêutica, kit para a preparação da composição farmacêutica, métodos de imagiologia e radioterapia do corpo de mamífero, de detecção, diagnóstico, prognóstico, previsão do resultado, cirurgia, estadiamento, tratamento, terapia, radioterapia, monitoramento do tratamento, monitoramento da progressão da doença e/ou monitoramento da terapia e de obtenção de uma imagiologia de locais e/ou tratamento de condições associadas à superexpressão ou localização de cmet in vivo, e, uso
GB201915206D0 (en) * 2019-10-21 2019-12-04 Ge Healthcare Ltd Use of cyclodextrins as a radiostabilizer
SE2050387A1 (en) * 2020-04-06 2021-10-07 Pvac Medical Tech Ltd Labelled substance and methods of detection of inflammation and infection using said substance
TW202305012A (zh) * 2021-03-22 2023-02-01 日商肽夢想股份有限公司 c-Met 蛋白質結合肽複合物

Family Cites Families (16)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5961955A (en) * 1997-06-03 1999-10-05 Coulter Pharmaceutical, Inc. Radioprotectant for peptides labeled with radioisotope
CA2472383A1 (en) 2001-12-27 2003-07-17 Van Andel Research Institute Monoclonal antibody imaging and therapy of tumors that express met and bind hepatocyte growth factor
ES2396368T3 (es) 2003-03-03 2013-02-21 Dyax Corporation Péptidos que se unen específicamente al receptor del HGF (CMET) y usos de los mismos
GB0305704D0 (en) * 2003-03-13 2003-04-16 Amersham Plc Radiofluorination methods
GB0420344D0 (en) * 2004-09-14 2004-10-13 Amersham Plc Diagnostic compounds
EP2043672A4 (en) 2006-07-07 2009-10-21 Univ Leland Stanford Junior SELECTIVE INHIBITORS OF CASPASES
GB0615211D0 (en) 2006-07-31 2006-09-06 Ge Healthcare Uk Ltd Asymmetric flouro-substituted polymethine dyes
EP3056509A1 (en) 2006-09-08 2016-08-17 Piramal Imaging SA Bombesin analogues for use in diagnosis
US8247534B2 (en) 2006-12-13 2012-08-21 Ge Healthcare As Synthesis of radiofluorinated peptide using microwave activation technology
WO2008083191A2 (en) * 2006-12-28 2008-07-10 Ge Healthcare As Radiofluorination methods
BRPI0721424A2 (pt) * 2007-03-01 2014-03-25 Bayer Schering Pharma Ag Métodos de radiofluoração
WO2008139207A2 (en) 2007-05-16 2008-11-20 Ge Healthcare As Labelled hgf binding peptides for imaging
GB0718957D0 (en) 2007-09-28 2007-11-07 Ge Healthcare Ltd Optical imaging agents
GB0718967D0 (en) * 2007-09-28 2007-11-07 Ge Healthcare Ltd Peptide imaging agents
GB0716897D0 (en) * 2007-08-30 2007-10-10 Univ Muenchen Tech Cancer imaging and treatment
GB0803477D0 (en) * 2008-02-26 2008-04-02 Ge Healthcare As Therapy selection method

Cited By (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2015507620A (ja) * 2011-12-20 2015-03-12 ジーイー・ヘルスケア・リミテッド 患者選別方法
US9956303B2 (en) 2011-12-20 2018-05-01 Ge Healthcare Limited Anti-met therapy for previously diagnosed cancer patients
US10548995B2 (en) 2013-08-21 2020-02-04 Ge Healthcare Limited Radiolabelling method
US10300156B2 (en) 2013-12-18 2019-05-28 Ge Healthcare Limited Radiotracer compositions and methods
US11311636B2 (en) 2013-12-18 2022-04-26 Ge Healthcare Limited Radiotracer compositions and methods

Also Published As

Publication number Publication date
JP2013540702A (ja) 2013-11-07
US20130149241A1 (en) 2013-06-13
WO2012022676A1 (en) 2012-02-23
PH12013500270A1 (en) 2013-04-01
KR101853993B1 (ko) 2018-05-02
CN103153350B (zh) 2016-06-29
EP2605802B1 (en) 2017-04-26
CN103153350A (zh) 2013-06-12
MX2013001939A (es) 2013-03-18
BR112013003469A2 (pt) 2016-06-21
EP2605802A1 (en) 2013-06-26
RU2594167C2 (ru) 2016-08-10
IL224463A (en) 2016-05-31
NZ606466A (en) 2014-11-28
SG187878A1 (en) 2013-03-28
US9533059B2 (en) 2017-01-03
AU2011290856B2 (en) 2014-12-04
RU2013105491A (ru) 2014-09-27
GB201013808D0 (en) 2010-09-29
ES2626410T3 (es) 2017-07-25
MY163136A (en) 2017-08-15
CA2807491A1 (en) 2012-02-23
MX348733B (es) 2017-06-27
KR20130135242A (ko) 2013-12-10
AU2011290856A1 (en) 2013-03-14
CA2807491C (en) 2019-06-04
CL2013000483A1 (es) 2014-03-07

Similar Documents

Publication Publication Date Title
JP6014592B2 (ja) ペプチド放射性トレーサー組成物
JP6824738B2 (ja) 放射性トレーサー組成物及び方法
JP2014505021A (ja) アポトーシス用petイメージング剤
US20210330824A1 (en) Purification method and compositions
JP5961191B2 (ja) テクネチウム標識ペプチド
JP6186371B2 (ja) 患者選別方法
HK1186119A (en) Peptide radiotracer compositions
HK1186119B (en) Peptide radiotracer compositions
HK1226050A1 (en) Purification method and compositions

Legal Events

Date Code Title Description
A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20140729

A621 Written request for application examination

Free format text: JAPANESE INTERMEDIATE CODE: A621

Effective date: 20140729

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20150804

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20151104

A02 Decision of refusal

Free format text: JAPANESE INTERMEDIATE CODE: A02

Effective date: 20151201

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160330

A911 Transfer to examiner for re-examination before appeal (zenchi)

Free format text: JAPANESE INTERMEDIATE CODE: A911

Effective date: 20160406

A131 Notification of reasons for refusal

Free format text: JAPANESE INTERMEDIATE CODE: A131

Effective date: 20160517

A521 Request for written amendment filed

Free format text: JAPANESE INTERMEDIATE CODE: A523

Effective date: 20160728

TRDD Decision of grant or rejection written
A01 Written decision to grant a patent or to grant a registration (utility model)

Free format text: JAPANESE INTERMEDIATE CODE: A01

Effective date: 20160830

A61 First payment of annual fees (during grant procedure)

Free format text: JAPANESE INTERMEDIATE CODE: A61

Effective date: 20160926

R150 Certificate of patent or registration of utility model

Ref document number: 6014592

Country of ref document: JP

Free format text: JAPANESE INTERMEDIATE CODE: R150

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250

R250 Receipt of annual fees

Free format text: JAPANESE INTERMEDIATE CODE: R250